# Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

> **NCT00458978** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 6 (actual)

## Conditions studied

- Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Recurrent Laryngeal Squamous Cell Carcinoma
- Recurrent Laryngeal Verrucous Carcinoma
- Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary
- Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma
- Recurrent Oral Cavity Verrucous Carcinoma
- Recurrent Oropharyngeal Squamous Cell Carcinoma
- Recurrent Salivary Gland Carcinoma
- Salivary Gland Squamous Cell Carcinoma
- Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary
- Stage IV Hypopharyngeal Squamous Cell Carcinoma
- Stage IV Laryngeal Squamous Cell Carcinoma
- Stage IV Laryngeal Verrucous Carcinoma
- Stage IV Lip and Oral Cavity Squamous Cell Carcinoma
- Stage IV Major Salivary Gland Carcinoma
- Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
- Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma
- Stage IV Oral Cavity Verrucous Carcinoma
- Stage IV Oropharyngeal Squamous Cell Carcinoma
- Tongue Carcinoma
- Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary

## Interventions

- **DRUG:** Cediranib Maleate
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00458978
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2013-05
- **Final completion:** 2014-07
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2015-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00458978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00458978, "Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00458978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*